Buy GLP-1 C + GLP-1 S (Cagrisema) Online — GLP Weight-Loss Peptide
Cagrilintide + Semaglutide — Dual Peptide Combination
Last updated April 2026 · COA-verified
GLP-1 C + GLP-1 S (Cagrisema) For Sale — Cagrisema combines cagrilintide (amylin analog) with semaglutide — targeting two separate appetite pathways for additive weight loss exceeding either compound alone.
- ~25% weight reduction in REDEFINE trials vs ~15% for semaglutide alone
- Dual amylin + GLP-1 mechanism — two completely separate appetite pathways
- Additive weight loss beyond what GLP-1 agonism alone achieves
- Amylin pathway reduces hunger through hypothalamic area postrema signaling
- Different mechanism from GIP-based approaches (tirzepatide, retatrutide)
COA verified · US domestic shipping
Amylin + GLP-1: Why the Combination Outperforms Either Alone
Cagrisema is a novel combination of cagrilintide (a long-acting amylin analog) and semaglutide. This combination targets two completely distinct appetite regulatory systems simultaneously — the amylin pathway and the GLP-1 pathway — achieving additive weight loss superior to semaglutide alone.
▸The Amylin Pathway
Amylin is co-secreted with insulin from pancreatic beta cells. It:
→Slows gastric emptying (like GLP-1, but through different receptors)
→Suppresses glucagon secretion
→Acts on area postrema and hypothalamus to reduce food intake
→Produces satiety through pathways entirely separate from GLP-1
Cagrilintide is a long-acting amylin analog with a half-life suitable for once-weekly dosing — designed specifically for co-administration with semaglutide.
▸Additive Efficacy
Because amylin and GLP-1 act through completely different receptors and pathways, combining them produces additive (not redundant) appetite suppression:
Phase III REDEFINE trials: Cagrisema showed ~25% body weight reduction — compared to ~15% for semaglutide alone at comparable doses. Demonstrating clear superiority of the combination.
▸Clinical Development
Cagrisema is in Phase III trials. Early data positions it between tirzepatide and retatrutide in efficacy, with the unique advantage of an entirely different mechanism from GIP-based dual/triple agonists.
Cagrisema: The Amylin + Semaglutide Combination That Rewrites Weight Loss Expectations
25% vs 15%
REDEFINE trials: cagrisema achieved ~25% weight reduction vs ~15% for semaglutide alone — a 67% improvement from adding the amylin pathway.
Unique Mechanism
Amylin receptor activation is completely distinct from GLP-1, GIP, and glucagon pathways — meaning it adds genuine additive efficacy rather than pathway overlap.
Different from GIP Combos
While tirzepatide and retatrutide use GIP receptor pathways, cagrisema uses the amylin system — offering a mechanistically distinct option for non-responders.
Phase III Pipeline
In Phase III trials with Novo Nordisk — positioned as the next generation of obesity pharmacotherapy beyond semaglutide monotherapy.
The Cagrisema Weight-Loss Signature
- ~25% weight reduction in REDEFINE trials vs ~15% for semaglutide alone
- Dual amylin + GLP-1 mechanism — two completely separate appetite pathways
- Additive weight loss beyond what GLP-1 agonism alone achieves
- Amylin pathway reduces hunger through hypothalamic area postrema signaling
- Different mechanism from GIP-based approaches (tirzepatide, retatrutide)
- Once-weekly injection — same convenience as semaglutide
- Phase III clinical program underway — strong regulatory pipeline
- Superior to semaglutide in head-to-head design
Cagrisema: Dual Pathway Weight Loss
Cagrisema combines two peptides acting through completely separate appetite pathways — explore the mechanism and outcomes.
Receptor: GLP-1 (Glucagon-Like Peptide-1)
Brain effect: Hypothalamic appetite suppression
Gut effect: Slows gastric emptying
Metabolic: Glucose-dependent insulin secretion
Receptor: Amylin (IAPP receptor)
Brain effect: Area postrema satiety signaling
Gut effect: Independent gastric slowing
Metabolic: Glucagon suppression
Why Combining Both Works
Amylin and GLP-1 act through completely different receptors and brain regions — their appetite-suppressing effects are additive, not redundant. This is why cagrisema achieves ~25% weight loss vs ~15% for semaglutide alone: two fully independent pathways are engaged simultaneously.
REDEFINE Phase III data. Cagrisema is in late-stage clinical development. For research and educational purposes only.
Running a Cagrisema Escalation
Protocol (Based on Phase III Design):
• Cagrilintide component: 2.4mg weekly
• Semaglutide component: 2.4mg weekly
• Combined weekly injection, subcutaneous
• Escalation over 16 weeks from starting dose
Phase III compound. Clinical guidance required for pharmaceutical use.
All information on this site is for educational purposes only. Always consult with a qualified healthcare provider before use. COA documentation is available for all products.
GLP-1 C + GLP-1 S (Cagrisema)
COA verified · Third-party tested · US domestic shipping
Buy Now View Stack ProtocolsGLP receptor agonists work via hypothalamic appetite regulation and metabolic enhancement — proven in large-scale clinical trials.
All Weight Loss PeptidesStacks Best With
What to Stack With Cagri-Sema
Weight LossGLP-1 S (Semaglutide)
Next-Gen GLP-1 Receptor Agonist for Weight Loss
Trusted GLP-1 S (Semaglutide) — Semaglutide (GLP-1 S) is a GLP-1 receptor agonist with clinical trials showing 15-20% body weight reduction — the most effective pharmacological weight loss agent studied.
Weight LossGLP-3 R (Retatrutide)
Triple Receptor Agonist — Next-Level Weight Loss
Buy GLP-3 R (Retatrutide) — Retatrutide (GLP-3 R) is a triple GLP-1/GIP/glucagon receptor agonist showing 24% body weight reduction in Phase II — the most potent weight loss peptide in clinical development.
Anti-AgingNAD+ 500mg
Cellular Energy & Longevity Cofactor
Verified NAD+ 500mg — NAD+ is the master cellular energy molecule that declines 50% by age 50 — supplementation restores sirtuin activity, DNA repair, and mitochondrial function.